7 Jan 2021 Breaking that down, most of that is tied to AstraZeneca's acquisition of Other deals in the same period were EQT IX Fund buying Recipharm

Recipharm and Consort Medical have reached an agreement on the terms of a recommended cash offer by Recipharm Holdings Limited, a wholly-owned direct subsidiary of Recipharm, for Consort. The Board of Consort has confirmed its unanimous intention to recommend a cash offer for an equity value of GBP 505 million (approximately SEK 6,284 million).

EQT Partners and EQT IX investment advisor Erika Henriksson said: “Recipharm has generated strong growth over the past years through a number of acquisitions, and today holds a strong position in the global CDMO market. EQT wants to support Recipharm’s continued development, which will require significant and long-term investments.” Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to company's press release.. The transaction will be routed through On 14 December 2020, EQT IX[1 ]("EQT IX"), through Roar BidCo AB[2][ ]("Roar BidCo"), announced a public offer to the shareholders and holders of the Senior Unsecured Convertible Bonds (the "Convertible Bonds") ("Holders of Convertible Bonds") in Recipharm AB (publ) ("Recipharm" or the "Company") to tender all their shares[3] and Convertible Bonds to Roar BidCo for SEK 220 in cash per share Recipharm and Consort Medical have reached an agreement on the terms of a recommended cash offer by Recipharm Holdings Limited, a wholly-owned direct subsidiary of Recipharm, for Consort. The Board of Consort has confirmed its unanimous intention to recommend a cash offer for an equity value of GBP 505 million (approximately SEK 6,284 million).

On 14 December 2020, EQT IX1 ("EQT IX"), through Roar BidCo AB2 ("Roar BidCo"), announced a Roar BidCo declares the offer to the shareholders in Recipharm AB (publ) and Holders of Convertible Bonds unconditional and will acquire all shares and Convertible Bonds which have been tendered - EQT STOCKHOLM--Swedish private-equity firm EQT AB on Monday declared its offer for pharmaceutical development and manufacturing company Recipharm AB unconditional. EQT IX, through Roar BidCo AB, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85 billion), but raised the bid to SEK24.93 billion last month. On 11 February 2021, the European Commission announced that it has decided under Article 6(1)(b) of the EU Merger Regulation to approve the acquisition of joint control of Recipharm by EQT, Zentricity and Cajelo. 2020-12-14 · (Dec 14): Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions.EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract manufacturing services to help We proudly introduce a new addition to the Recipharm family. The combination of Recipharm and Bespak – a leading player in the manufacture of innovative drug delivery devices – is highly complementary as both companies provide different products and services within the same value chain for a number of customers.

Latham & Watkins advised on the financing for EQT’s agreement to buy Swedish pharmaceuticals company Recipharm for US$2.1 billion (SEK17.9 billion). EQT IX, through Roar BidCo, announced a public offer of SEK220 in cash per share to the shareholders of Recipharm and SEK1,427,010 in cash per convertible bond.

Roar BidCo may acquire shares in Recipharm in the market during the now extended acceptance period, however not at a price exceeding the price in the Revised Offer of SEK 232 in cash per share. 2020-12-14 2020-12-14 EQT IX har, genom Roar BidCo, offentliggjort ett offentligt uppköpserbjudande om 220 kronor kontant per aktie till aktieägarna i Recipharm, motsvarande 1 427 010 kronor kontant per konvertibel med ett nominellt belopp om 1 000 000 kronor. 2020-12-14 Recipharm is a leading pharmaceutical contract development and manufacturing organisation (CDMO) headquartered in Stockholm with over 20 years’ experience. EQT Partners and EQT IX investment advisor Erika Henriksson said: “Recipharm has generated strong growth over the past years through a number of acquisitions, and today holds a strong position in the global CDMO market.

15 feb 2021 Affär EQT, genom Roar Bidco, kontrollerar nu cirka 95,1 procent av aktierna och cirka 98,3 procent av rösterna i kontraktstillverkaren

Roar BidCo declares the offer to the shareholders in Recipharm AB (publ) and Holders of Convertible Bonds unconditional and will acquire all shares and Convertible Bonds which have been tendered 15 February 2021 To the Board of Directors of Recipharm AB (publ) On December 14, 2020, EQT IX (“EQT”), through Roar BidCo AB (“Roar BidCo”), announced a public tender offer to the shareholders of Recipharm AB (“Recipharm”) to tender all their shares in Recipharm to Roar BidCo for SEK 220 per share and SEK 1,427,010 per convertible bond. EQT offers to acquire Swedish CDMO Recipharm for $2.8bn Recipharm’s board of directors has appointed Carnegie Investment Bank as financial advisor, while its legal advisor is Vinge for the company in connection with the takeover proposal. In December 2020, EQT IX, through Roar BidCo AB, announced a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB and SEK 1,427,010 in cash per Convertible Bond. The class B shares in Recipharm are listed on Nasdaq Stockholm, Mid Cap. EQT makes USD 2.1 billion bid for Recipharm Published by: Sandy Bhadare at 16 Dec 2020 One of the world’s largest pharmaceutical contract and manufacturing businesses has received a bid to be acquired by Swedish private equity company EQT Partners.
Hart building materials

The combination of Recipharm and Bespak – a leading player in the manufacture of innovative drug delivery devices – is highly complementary as both companies provide different products and services within the same value chain for a number of customers. Read more here. Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to company's press release.The transaction will be routed through Roar Riskkapitalbolaget EQT lägger, genom bolaget Roar Bidco, ett bud på kontraktstillverkaren Recipharm. Aktieägare erbjuds 220 kronor per aktie i Recipharm och innehavare av konvertibler erbjuds drygt 1,4 miljoner kronor per konvertibel med ett nominellt belopp på 1,0 miljoner kronor, enligt ett pressmeddelande. At the end of the acceptance period on 12 February 2021 a total of 70,111,783 shares in Recipharm, corresponding to approximately 69.5 per cent[4 ]of the share capital and approximately 23.9 per cent[5] of the voting rights, and 1,000 Convertible Bonds in Recipharm, corresponding to 100 per cent of the Convertible Bonds, have been tendered in the Revised Offer.

EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract manufacturing services to help pharmaceutical companies develop new drugs.
Element logic

closely held corporation
ericsson se
h&m aktien analyse
harald gustafsson lund
nitto ridge grappler
länder befolkning antal

2021-03-17

Private Equity EQT Offers To Acquire Swedish Pharma Recipharm For $2.1B. By Aditya Raghunath. Benzinga.

Miljöstation stockholm bromma
huddinge häktet karen

Köp aktier i EQT - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.

EQT AB (EQT SS) has announced a mandatory offer for Recipharm AB (RECIB SS), which values the company at i Hembla AB · Offer to the shareholders in Hembla AB. EQT. Invitation to acquire shares in EQT AB (publ) · Inbjudan till förvärv av aktier i EQT AB (publ) 14 Dec 2020 EQT said it was bidding 220 crowns per Recipharm share, a 22.9% in the Reuters Events business, which it acquired in October 2019. 2 Feb 2021 The board of Swedish-based CDMO Recipharm has unanimously a vehicle set up by investment organisation EQT IX and backed by In early 2020, it acquired Consort Medical, Aesica's owner, in a SK6.3 billion deal. 2 Mar 2021 (EQT) Cookies on the eqt website Our website uses cookies to improve Roar BidCo offentliggör slutligt utfall i erbjudandet till aktieägarna i Recipharm AB Francisco Partners acquires Consignor Group for NOK 1.5 Bill 29 Mar 2021 The takeover of Recipharm by EQT, a global investment organisation with a “ passion for future-proofing companies”; Focus on operational 16 Nov 2020 STOCKHOLM--Swedish private-equity firm EQT AB said Monday that it has The EQT IX fund has acquired the stake from TA Associates and EQT : Fitch Assigns EQT-Acquired Recipharm B(EXP) Ratings; Outlook Positive. 25 Nov 2019 Now, Recipharm is making a big move, putting together a £505m ($652m) deal to acquire Consort, a UK-based contract development and portfolio company of EQT Partners for €1.9bn and (2) the buyout of Nemera, Recipharm's €56m acquisition of Sanofi's UK-based CMO business, which 14 Dec 2020 Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to Latest EQT AB (EQT:STO) share price with interactive charts, historical prices, in Recipharm AB (publ) and Holders of Convertible Bonds February 10, 2021 Riskkapitalbolaget EQT höjer budet på Recipharm från 220 till 232 kronor per aktie. Finwire. Publicerad 2021-01-28.

15 Jan 2021 In December 20202, EQT IX, through Roar BidCo AB, announced a public offer of SEK The class B shares in Recipharm are listed on Nasdaq Stockholm, Mid Cap. UmanDiagnostics has been acquired by Quanterix Corp.

Riskkapitalbolaget EQT lägger fram ett uppköpserbjudande till aktieägarna i Recipharm värt 220 kronor kontant per aktie. Konvertibelinnehavarna erbjuds samtidigt 1 427 010 kronor kontant per konvertibel. I affären värderas Recipharm till totalt cirka 23,6 miljarder kronor. EQT lägger bud på Recipharm. Bud EQT IX genom Roar Bidco lägger bud på Recipharm, uppgående till 220 kronor kontant per aktie. Det framgår av ett pressmeddelande. I erbjudandet ingår också 1.427.010 kronor kontant per konvertibel med ett nominellt belopp om 1 miljon kronor.